Riskpilot← Back to searchSign inGet full accessHepaPredict AB
ABActiveOrg 5590577044Nobels Väg 16Technical testing and analysis · NACE 7120Est. 20163 employees
Revenue 2024
SEK 4,2M
+20% vs 2023
EBITDA margin
14.8%
-36% vs 2023
Equity ratio
74.1%
Financial strength
Net profit 2024
SEK 465K
-19% vs 2023
| Revenue | SEK 4,2M | +20% |
| EBITDA | SEK 615K | -36% |
| Net profit | SEK 465K | -19% |
| Total assets | SEK 3,8M | +13% |
| Equity | SEK 2,8M | +20% |
| Employees | 3 | — |
Legal name
HepaPredict AB
Org number
5590577044
Legal form
Aktiebolag
NACE code
7120 · Technical testing and analysis
Founded
6 april 2016
Share capital
SEK 50 000
Employees
3 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Dessutom har verkställande direktören rätt att teckna firman beträffande löpande förvaltningsåtgärder
Company purpose
Bolaget ska bedriva utvecklingsarbete av in vitro modeller för prediktion och diagnostik av levertoxicitet, för att producera, marknadsföra och sälja produkter inom området levertoxicitet samt att bedriva en serviceverksamhet för identifiering av ämnen som är levertoxiska.
Address
Nobels Väg 16
Email
volker.lauschke@hepapredict.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 840 | 918 | 1 697 | 4 870 | 2 715 | 4 876 | 3 479 | 4 168 |
| Staff expenses | — | — | — | — | — | — | — | — | — |
| EBITDA | −7 | 314 | 156 | 154 | 1 189 | 421 | 721 | 967 | 615 |
| Depreciation & amort. | −0 | −6 | −10 | −10 | −10 | −10 | −4 | −45 | −45 |
| EBIT | −7 | 308 | 146 | 144 | 1 179 | 411 | 717 | 922 | 570 |
| Net financials | — | — | −6 | −2 | — | — | −11 | 1 | — |
| Profit before tax | −7 | 226 | 108 | 108 | 882 | 301 | 531 | 737 | 607 |
| Tax | −0 | −48 | −24 | −24 | −189 | −63 | −111 | −161 | −142 |
| Net profit | −7 | 178 | 84 | 84 | 693 | 238 | 420 | 576 | 465 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 98 | 657 | 677 | 796 | 1 925 | 2 143 | 2 550 | 3 326 | 3 754 |
| Equity | 43 | 221 | 304 | 388 | 1 082 | 1 319 | 1 740 | 2 316 | 2 780 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 55 | 354 | 258 | 259 | 398 | 269 | 88 | 102 | 102 |
| Total debt | 55 | 354 | 258 | 259 | 398 | 269 | 88 | 102 | 102 |
EBITDA margin
14.8%
This company
15.8%
Market median
-6% vs market
20162024
Equity ratio
74.1%
This company
38.2%
Market median
+94% vs market
20162024
Return on equity
16.7%
This company
18.4%
Market median
+9% vs market
20162024
Net profit margin
11.2%
This company
8.1%
Market median
+38% vs market
20162024
Asset turnover
1.11×
This company
1.12×
Market median
+1% vs market
20162024
Debt / equity
0.35×
This company
0.62×
Market median
+44% vs market
20162024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Bolagsverket / SCB · Period 2016-04-01 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
VM Chief Executive Officer | Chief Executive Officer | 2020 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2020 | — | — | |
| Chairman | 2020 | — | — | |
| Board of Directors | 2020 | — | — | |
| Deputy Board Member | 2020 | — | — | |
| Board of Directors | 2022 | — | — |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of HepaPredict AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Volker Martin Lauschke | Chief Executive Officer | 0 companies |
| Pirkko Vilja Päivikki Tamsen | Board of Directors | 0 companies |
| Magnus Axel Lorenzo Ingelman-Sundberg | Chairman | 0 companies |
| Lars Håkan Randahl | Board of Directors | 0 companies |
| Bengt Anders Josef Malmström | Deputy Board Member | 0 companies |
| Bo Erik Qwarnström | Board of Directors | 0 companies |